TiGenix : Licenses Exclusive Marketing And Distribution Rights For Chondrocelect To Swedish Orphan Biovitrum
4/3/2014 8:13:40 AM
LEUVEN, Belgium, April 3, 2014 (GLOBE NEWSWIRE) -- TiGenix NV (Euronext Brussels: TIG), the European leader in cell therapy, announced today that it has licensed the marketing and distribution of ChondroCelect, the cell-based medicinal product for the repair of cartilage defects of the knee, to the international specialty healthcare company dedicated to rare diseases, Swedish Orphan Biovitrum AB ('Sobi', NASDAQ OMX Stockholm: SOBI).
Help employers find you! Check out all the jobs and post your resume.
comments powered by